Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE trial of prolonged-release fampridine in multiple sclerosis
2013-003600-40Phase 3Completed
- Sponsor
- Biogen
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Fampridine with Placebo (2 arms). Primary endpoint: MSWS-12 responder rate. Started May 2014; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-003600-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003600-40.